The FDA has approved lirafugratinib for advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement based on the phase 1/2 ReFocus trial.
|Videos|June 1, 2017
Use of SBRT in Treating Pancreatic Cancer
Author(s)Sarah E. Hoffe, MD
This video highlights the evolution of stereotactic body radiation therapy in the treatment of pancreatic cancer.
Advertisement
In this video, Sarah E. Hoffe, MD, of the Moffitt Cancer Center in Tampa, Florida, discusses the evolution of stereotactic body radiation therapy (SBRT) for the treatment of pancreatic cancer.
Hoffe also highlights a recent study
Advertisement
Related to this article
Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.
A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of pancreatic ductal adenocarcinoma.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
The FDA granted breakthrough therapy designation to daraxonrasib/chemotherapy for treatment-naive pancreatic adenocarcinoma based on phase 1/2 trial data.
Lutetium Lu 177 dotatate injection has been approved by the FDA for patients with somatostatin receptor-positive GEP-NETs.
The FDA cleared TriSalus’s TriNav Advance device, which extends the SmartValve-based drug delivery technology to improve tumor penetration during liver embolization.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
Daratumumab Combo Yields Responses in Cardiac-Involved AL Amyloidosis Trials
3
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
4
Epcoritamab Combo Receives Canadian Approval in R/R Follicular Lymphoma
5